{"relation": [["Adverse Reaction", "", "Dizziness", "Upper respiratory tract infection", "Headache", "Fatigue"], ["Placebo", "(n=678)", "19 (2.8%)", "4 (0.6%)", "12 (1.8%)", "12 (1.8%)"], ["Alfuzosin Hydrochloride Extended-Release Tablets", "(n=473)", "27 (5.7%)", "14 (3%)", "14 (3%)", "13 (2.7%)"]], "pageTitle": "Alfuzosin - FDA prescribing information, side effects and uses", "title": "Table 1 \u2014Adverse Reactions Occurring in \u22652% of Alfuzosin Hydrochloride Extended-Release Tablets-Treated Patients and More Frequently than with Placebo in 3-Month Placebo-Controlled Clinical Trials", "url": "http://www.drugs.com/pro/alfuzosin.html", "hasHeader": true, "headerPosition": "FIRST_ROW", "tableType": "RELATION", "tableNum": 0, "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438042988399.65/warc/CC-MAIN-20150728002308-00320-ip-10-236-191-2.ec2.internal.warc.gz", "recordEndOffset": 410532371, "recordOffset": 410496828, "tableOrientation": "HORIZONTAL", "TableContextTimeStampBeforeTable": "{55576=Pregnancy Category B. Alfuzosin hydrochloride extended-release tablets are not indicated for use in women, and there are no studies of Alfuzosin in pregnant women. Alfuzosin was not teratogenic, embryotoxic or fetotoxic in rats at plasma exposure levels (based on AUC of unbound drug) up to 1200 times (maternal oral dose of 250 mg/kg/day) the maximum recommended human dose (MRHD) of 10 mg. In rabbits administered up to 3 times the MRHD (based on body surface area) (maternal oral dose of 100 mg/kg/day) no embryofetal toxicity or teratogenicity was observed. Gestation was slightly prolonged in rats at exposure levels (based on AUC of unbound drug) approximately 12 times (greater than 5 mg/kg/day oral maternal dose) the MRHD, but difficulties with parturition were not observed., 3308=Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088., 967=Distributed by: Sun Pharmaceutical Industries, Inc. Cranbury, NJ 08512 ISS. 11/2014 PJPI0348C}", "TableContextTimeStampAfterTable": "{29504=Drugs.com provides accurate and independent information on more than 24,000 prescription drugs, over-the-counter medicines and natural products. This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment. Data sources include Micromedex\u00ae (updated July 13th, 2015), Cerner Multum\u2122 (updated July 2nd, 2015), Wolters Kluwer\u2122 (updated July 2nd, 2015) and others. To view content sources and attributions, please refer to our editorial policy., 30781=Copyright \u00a9 2000-2015 Drugs.com. All rights reserved.}", "textBeforeTable": "Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. The incidence of adverse reactions has been ascertained from 3 placebo-controlled clinical trials involving 1,608 men where daily doses of 10 mg\u00a0and 15 mg Alfuzosin were evaluated. In these 3 trials, 473 men received Alfuzosin hydrochloride extended-release tablets 10 mg. In these trials, 4% of patients taking Alfuzosin hydrochloride extended-release tablets 10 mg withdrew from the trial due to adverse reactions, compared with 3% in the placebo group. Table 1 summarizes adverse reactions that occurred in \u22652% of patients receiving Alfuzosin hydrochloride extended-release tablets, and at a higher incidence than that of the placebo group. In general, the adverse reactions seen in long-term use were similar in type and frequency to the events described below for the 3-month trials. Clinical Trials Experience Adverse Reactions Use with caution in patients with acquired or congenital QT prolongation or who are taking medications that prolong the QT interval [see Clinical Pharmacology (12.2)]. Patients with Congenital or Acquired QT Prolongation If symptoms of angina pectoris should appear or worsen, Alfuzosin hydrochloride extended-release tablets should be discontinued. Coronary Insufficiency", "textAfterTable": "The following adverse reactions, reported by between 1% and 2% of patients receiving Alfuzosin hydrochloride extended-release tablets and occurring more frequently than with placebo, are listed alphabetically by body system and by decreasing frequency within body system: Body as a whole: pain Gastrointestinal system:\u00a0abdominal pain, dyspepsia, constipation, nausea Reproductive system:\u00a0impotence Respiratory system:\u00a0bronchitis, sinusitis, pharyngitis Signs and Symptoms of Orthostasis in Clinical Trials: The adverse reactions related to orthostasis that occurred in the double-blind phase 3 trials with Alfuzosin 10 mg are summarized in Table 2. Approximately 20% to 30% of patients in these trials were taking antihypertensive medication. Table 2\u2014 Number (%) of Patients with Symptoms Possibly Associated with Orthostasis in 3-Month Placebo-Controlled Clinical Trials Symptoms Placebo Alfuzosin Hydrochloride Extended-Release Tablets \u00a0 (n=678) (n=473) Dizziness 19 (2.8%) 27 (5.7%) Hypotension or postural hypotension 0", "hasKeyColumn": true, "keyColumnIndex": 0, "headerRowIndex": 0}